Medications

Budesonide yields durable reduction in eGFR for IgA nephropathy

For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...

page 2 from 11